RxDoctor Payments Data

Joel Knight, MD

Internal Medicine · Georgetown, KYNPI 1235292343

Payments from drug & device makers

$7,703in general payments, 2019–2025

Across 457 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$747
  • AbbVie$712
  • Corium, LLC$463
  • Pfizer$429
  • Lilly USA, LLC$370
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$7,65399%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,703 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$28,382
Medicare patients
84
Services billed
360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$66,936
FarxigaDapagliflozin Propanediol65$56,187
JanuviaSitagliptin Phosphate46$48,864
MounjaroTirzepatide45$47,625
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$47,148
XareltoRivaroxaban37$36,034
Stiolto RespimatTiotropium Br/Olodaterol Hcl65$35,506
JardianceEmpagliflozin26$27,091
LinzessLinaclotide29$22,567
EliquisApixaban37$20,823
Combivent RespimatIpratropium/Albuterol Sulfate26$19,974
Humulin R U-500 KwikpenInsulin Regular, Human12$16,948
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$10,964
Breo ElliptaFluticasone/Vilanterol19$7,426
MovantikNaloxegol Oxalate16$7,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimStiolto Respimat, Jardiance, Combivent Respimat, Spiriva Respimat$316$89,219130 claims
Novo NordiskOzempic$334$66,93671 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$2,073$65,538101 claims
AstraZenecaFarxiga, Symbicort$747$63,27694 claims
MerckJanuvia$57$48,86446 claims
Lilly USA, LLCMounjaro$370$47,62545 claims
PfizerEliquis, Abrysvo$429$26,23754 claims
AbbVieLinzess$712$22,56729 claims
Arbor Pharmaceuticals, Inc.Edarbi$73$6,60818 claims
Sanofi-aventis U.S. LLCLantus$52$2,89125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Georgetown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →